Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Files An 8-K Results of Operations and Financial Condition
Item2.02 Results of Operations and Financial Condition
On March9, 2017, Aquinox Pharmaceuticals, Inc. (the Company)
issued a press release announcing financial results for the year
ended December31, 2016. The full text of the press release
announcing such results is attached as Exhibit99.1 to this
Current Report on Form 8-K and is incorporated herein by
reference.
The information in this current report on Form 8-K and the press
release attached as Exhibit 99.1 hereto is being furnished, but
shall not be deemed filed for purposes of Section18 of the
Securities Exchange Act of 1934, as amended (Exchange Act), and
is not incorporated by reference into any filing of the Company
under the Securities Act of 1933, as amended, or the Exchange
Act, whether made before or after the date hereof, regardless of
any general incorporation language in such filing.
Item9.01. Financial Statements and Exhibits.
| (d) | Exhibits |
| Number |
Description |
|
| 99.1 |
Press Release of Aquinox Pharmaceuticals, Inc. dated March 9, 2017 |
About Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP)
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology. Its primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells. The Company’s product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. The Company is developing AQX-1125 as a treatment in interstitial cystitis/bladder pain syndrome (IC/BPS), a chronic inflammatory disease of the bladder. It has completed and reported results from its Leadership trial, which is a multicenter, randomized, double-blind, placebo-controlled, Phase II clinical trial. Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Recent Trading Information
Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) closed its last trading session up +0.08 at 17.43 with 91,668 shares trading hands.
